Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jan 9;41(2):290-293.
doi: 10.1016/j.vaccine.2022.11.065. Epub 2022 Dec 2.

Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022

Anna Stoliaroff-Pepin  1 , Caroline Peine  2 , Tim Herath  3 , Johannes Lachmann  3 , Delphine Perriat  3 , Achim Dörre  4 , Andreas Nitsche  5 , Janine Michel  5 , Marica Grossegesse  5 , Natalie Hofmann  5 , Thomas Rinner  5 , Claudia Kohl  5 , Annika Brinkmann  5 , Tanja Meyer  6 , Brigitte G Dorner  6 , Daniel Stern  6 , Fridolin Treindl  6 , Sascha Hein  7 , Laura Werel  7 , Eberhard Hildt  7 , Sven Gläser  8 , Helmut Schühlen  9 , Caroline Isner  10 , Alexander Peric  11 , Ammar Ghouzi  12 , Annette Reichardt  13 , Matthias Janneck  14 , Guntram Lock  15 , Lars Schaade  16 , Ole Wichmann  3 , Thomas Harder  3
Affiliations
Multicenter Study

Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022

Anna Stoliaroff-Pepin et al. Vaccine. .

Abstract

We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE was 89 % (95 % CI 84-93 %) overall, 79 % in patients with more than two comorbidities and 77 % in adults aged 60-75 years. A third dose increased the VE to more than 93 % in all patient-subgroups.

Keywords: COVID-19; Case-control study; Delta; Hospitalization; SARS-CoV-2; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. G. received payment/honoraria from Astra Zeneca, Boehringer Ingelheim, Roche Pharma and Berlin Chemie, this had no influence on this work; all other authors reported no conflicts of interest.

Figures

Fig. 1
Fig. 1
Vaccine effectiveness for two and three vaccination doses, endpoint severe COVID-19 (hospitalization). Vaccine effectiveness for all participants and subgroups is shown. Calculation of VE was performed as described in the Supplementary Methods. aICU treated cases versus controls with no ICU treatment.
See this image and copyright information in PMC

References

    1. Robert-Koch-Institute. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). 2022; Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsb....
    1. Sharif N., et al. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol. 2021;12 - PMC - PubMed
    1. Skowronski D.M., et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec. Canada Clin Infect Dis. 2022 - PMC - PubMed
    1. Feikin D.R., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–944. - PMC - PubMed
    1. Mahumud R.A., et al. Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. Vaccines (Basel) 2022;10(2) - PMC - PubMed

Publication types